Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 118

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 118
---
 any underlying assumptions, are forward -lookingstatements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” and similar expressions may identify forward -lookingstatements, but the absence of these words does not mean that a statement is not forward -looking. Forward -lookingstatements in this proxy statement/prospectus may include, for example, statements about: •the ability of NLS and Kadimastem to consummate the Merger; •the risks that the consummation of the Merger is substantially delayed or does not occur, for example due to the failure to obtain shareholder approval; •the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement; •the expected benefits of the Merger; •the unexpected costs related to the proposed Merger; •the financial and business performance of NLS, including financial projections and business metrics and any underlying assumptions thereunder; •changes in NLS’s and Kadimastem’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; •the implementation, market acceptance and success of NLS’s and Kadimastem’s business model; •NLS’s and Kadimastem’s ability to scale in a cost -effectivemanner; •developments and projections relating to NLS’s and Kadimastem’s competitors and industry; •NLS’s and Kadimastem’s expectations regarding its ability to obtain and maintain intellectual property protection and not infringe on the rights of others; •expectations regarding the time during which NLS will be an EGC under the JOBS Act; •NLS’s and Kadimastem’s future capital requirements and sources and uses of cash; •NLS’s and Kadimastem’s ability to obtain funding for their operations; •NLS’s and Kadimastem’s business, expansion plans and opportunities; •NLS’s and Kadimastem’s management and board of directors; •the listing of NLS’s securities on Nasdaq; •geopolitical risk and changes in applicable laws or regulations; •fluctuations in exchange rates between the foreign currencies in which NLS and Kadimastem typically do business and the United States dollar; and •the outcome of